Nkarta, Inc. (NKTX) Income Statement

NASDAQ: NKTXRevenue, profits, margins and EPS over 8 years.

NKTX 2025 at a glance

Fiscal year ended December 31, 2025 · U.S. dollars
Revenue
$0
2025 · hover or tap a bar for each year
2018: $6.5M2019: $115,385 (−98.2%)2020: $385 (−99.7%)2021: $0 (−100.0%)2022: $02023: $02024: $02025: $0
20182025
Gross profit
−$9.2M
2025 · hover or tap a bar for each year
2018: $2.3M2019: $98,168 (−95.7%)2020: −$1.0M (−1,167.6%)2021: −$2.1M2022: −$6.6M2023: −$5.9M2024: −$9.2M2025: −$9.2M
20182025
Operating income
−$121.2M
2025 · hover or tap a bar for each year
2018: −$356,4492019: −$22.3M2020: −$51.5M2021: −$86.4M2022: −$119.0M2023: −$131.7M2024: −$128.2M2025: −$121.2M
20182025
Net income
−$104.1M
2025 · hover or tap a bar for each year
2018: −$274,5032019: −$21.1M2020: −$91.4M2021: −$83.9M2022: −$119.4M2023: −$117.5M2024: −$108.8M2025: −$104.1M
20182025
EPS (diluted)
−$1.40
2025 · hover or tap a bar for each year
2019: −$2.352020: −$7.762021: −$2.622022: −$2.652023: −$2.402024: −$1.662025: −$1.40
20182025

NKTX revenue and net income

RevenueNet incomeNet margin (right axis)

NKTX profit margins

GrossOperatingNet

NKTX growth rates

to 2025
1 year3 years5 years10 years
Revenue————
Gross profit————
Operating income————
Net income————
EPS (diluted)————

1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.

NKTX quarterly EPS vs estimates

Reported EPSAnalyst estimate

Nkarta beat the analyst EPS estimate in 4 of the last 8 quarters. Next report: November 9, 2026 (estimate $-0.40).

NKTX income statement

Nkarta, Inc. annual income statement
20252024202320222021202020192018
Revenue$0$0$0$0$0$385$115,385$6.5M
Cost of revenue$9.2M$9.2M$5.9M$6.6M$2.1M$1.0M$17,217$4.3M
Gross profit−$9.2M−$9.2M−$5.9M−$6.6M−$2.1M−$1.0M$98,168$2.3M
Research & development$90.4M$96.7M$90.9M$90.9M$63.4M$36.2M$17.2M$4.3M
Sales, general & admin$31.6M$31.4M$34.9M$28.1M$23.0M$15.3M$5.2M$2.7M
Total operating expenses$112.0M$128.2M$125.8M$119.0M$86.4M$51.5M$22.5M$6.9M
Operating income−$121.2M−$128.2M−$131.7M−$119.0M−$86.4M−$51.5M−$22.3M−$356,449
Interest income$15.5M$19.3M$13.5M$5.6M$370,000$313,000$304,106$81,946
Interest expense———$5.6M$2.1M$313,000$473,000$0
Income before taxes−$104.1M−$108.8M−$117.5M−$113.8M−$86.1M−$91.4M−$21.1M−$274,503
Income taxes——$5.3M$5.6M−$2.1M−$41.0M$1.8M$81,946
Net income−$104.1M−$108.8M−$117.5M−$119.4M−$83.9M−$91.4M−$21.1M−$274,503
EBITDA−$94.9M−$99.6M−$120.5M−$116.3M−$84.7M−$50.7M−$20.0M−$91,289
EPS (diluted)−$1.40−$1.66−$2.40−$2.65−$2.62−$7.76−$2.35—
Gross margin—————−272,207.8%85.1%35.1%
Operating margin—————−13,378,701.3%−19,368.7%−5.4%
Net margin—————−23,730,129.9%−18,265.7%−4.2%

Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in NKTX's financial statements (latest annual report filed March 25, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.

NKTX financial results

Nkarta reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $104.1 million. Diluted earnings per share came to −$1.40.

See the NKTX stock overview for the latest quote and news, or the NKTX chart for price history and technical indicators.

NKTX income statement FAQ

Does Nkarta have revenue?

Nkarta reported no revenue for fiscal year 2025, which ended on December 31, 2025.

Is Nkarta profitable?

No. Nkarta reported a net loss of $104.1 million in fiscal 2025.

How much does Nkarta spend on research and development?

Nkarta spent $90.4 million on research and development in fiscal 2025.

What are Nkarta's earnings per share?

Nkarta earned $-1.40 per diluted share in fiscal 2025, compared with $-1.66 a year earlier.

When will Nkarta report its next earnings?

Nkarta is expected to report results for the quarter ending September 30, 2026 on November 9, 2026.

When does Nkarta's fiscal year end?

Nkarta's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 25, 2026.

Biotechnology income statements